Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE)
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria (comparative period):
- Patients With Type 2 Diabetes diagnosed for at least 1 year,
- Treated with lifestyle interventions and metformin at the maximum tolerated dosage (with a minimum daily dosage of 1g), either alone or in combination with an oral insulin secretagogue (sulfonylurea, glinide or DiPeptidyl Peptidase IV inhibitor), for more than 3 months,
- 7.5% < HbA1c <= 12%,
- Body Mass Index (BMI) between 25 and 40 kg/m2 inclusively,
- Ability and willingness to perform PG (Plasma Glucose) self monitoring using the sponsor-provided glucose meter and to complete the patient diary,
- Willingness and ability to comply with the study protocol,
- Signed informed consent obtained prior to any study procedure.
Inclusion criteria (extension period):
- Patients treated with liraglutide (at the maximal tolerated dosage), having a mean FPG ≥ 250 mg/dL at visit 10 (Week 12) or visit 11 (Week 18), or a HbA1c≥ 7% at visit 12 (Week 24)
- Dosage of metformin compliant with the inclusion criteria of visit 1 (i.e. maximum tolerated dosage, with a minimum daily dosage of 1g), and maintained stable during the comparative period.
Exclusion criteria:
- Previous treatment with Glucagon Like Peptide-1 analogues or insulin in the past year (except in case of temporary treatment for gestational diabetes, surgery, hospitalization...),
- Treatment with thiazolidinediones or α-Glucosidases inhibitors within 3 months prior to study entry,
- Diabetes other than Type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agents intake),
- Pregnant women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method),
- Lactating women,
- Hospitalized patients (except hospitalization for routine diabetes check-up),
- Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to study entry, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study, documented by a retina examination within 2 years prior to study entry,
- Impaired renal function (creatinine clearance < 60 mL/mn),
- Impaired hepatic function (Alanine Aminotransferase, Aspartate Aminotransferase 2.5 times the upper limit of normal range),
- Personal or family history of medullary thyroid carcinoma,
- Multiple endocrine neoplasia syndrome type 2,
- Severe gastro-intestinal disease (including inflammatory bowel disease or diabetic gastroparesis),
- Congestive heart failure,
- History of acute pancreatitis,
- Treatment with corticosteroids with potential systemic action for more than 10 days within 3 months prior to study entry,
- Alcohol or drug abuse in the past 5 years,
- History of sensitivity to the study drugs or to drugs with a similar chemical structure.
- Night shift worker,
- Presence of any condition (medical, psychological, social or geographical), current or anticipated that would compromise the patients safety or limit the patient successful participation in the study,
- Participation in a clinical trial (drug or device) within 3 months prior to study entry,
- Refusal or inability to give informed consent to participate in the study,
- Patient is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
Additional exclusion criteria for the extension period:
- Treatment with oral antidiabetic drugs other than metformin and patient's usual sulfonylurea if any, or with insulin during the comparative period (except in case of an emergency, for a period of time less than 7 days),
- Treatment with corticosteroids with potential systemic action within the last 3 months of the comparative period.
- History of sensitivity to insulin glargine.
Sites / Locations
- Investigational Site Number 840023
- Investigational Site Number 840002
- Investigational Site Number 840047
- Investigational Site Number 840017
- Investigational Site Number 840036
- Investigational Site Number 840037
- Investigational Site Number 840045
- Investigational Site Number 840048
- Investigational Site Number 840033
- Investigational Site Number 840019
- Investigational Site Number 840039
- Investigational Site Number 840042
- Investigational Site Number 840043
- Investigational Site Number 840028
- Investigational Site Number 840034
- Investigational Site Number 840026
- Investigational Site Number 840022
- Investigational Site Number 840029
- Investigational Site Number 840009
- Investigational Site Number 840051
- Investigational Site Number 840050
- Investigational Site Number 840031
- Investigational Site Number 840004
- Investigational Site Number 840010
- Investigational Site Number 840038
- Investigational Site Number 840030
- Investigational Site Number 840012
- Investigational Site Number 840044
- Investigational Site Number 840015
- Investigational Site Number 840008
- Investigational Site Number 840027
- Investigational Site Number 840011
- Investigational Site Number 840005
- Investigational Site Number 840052
- Investigational Site Number 840049
- Investigational Site Number 840006
- Investigational Site Number 840035
- Investigational Site Number 840016
- Investigational Site Number 840020
- Investigational Site Number 840024
- Investigational Site Number 840001
- Investigational Site Number 840007
- Investigational Site Number 840013
- Investigational Site Number 840014
- Investigational Site Number 840046
- Investigational Site Number 040-006
- Investigational Site Number 040-007
- Investigational Site Number 040-003
- Investigational Site Number 040-005
- Investigational Site Number 040-002
- Investigational Site Number 040-001
- Investigational Site Number 040-004
- Investigational Site Number 076-004
- Investigational Site Number 076-007
- Investigational Site Number 076-001
- Investigational Site Number 076-006
- Investigational Site Number 076-005
- Investigational Site Number 076-002
- Investigational Site Number 124-003
- Investigational Site Number 124-001
- Investigational Site Number 124-006
- Investigational Site Number 124-004
- Investigational Site Number 124-008
- Investigational Site Number 124-007
- Investigational Site Number 203001
- Investigational Site Number 203003
- Investigational Site Number 203005
- Investigational Site Number 203002
- Investigational Site Number 203006
- Investigational Site Number 246003
- Investigational Site Number 246001
- Investigational Site Number 246002
- Investigational Site Number 246004
- Investigational Site Number 250-007
- Investigational Site Number 250-017
- Investigational Site Number 250-003
- Investigational Site Number 250-011
- Investigational Site Number 250-008
- Investigational Site Number 250-012
- Investigational Site Number 250-009
- Investigational Site Number 250-004
- Investigational Site Number 250-006
- Investigational Site Number 250-021
- Investigational Site Number 250022
- Investigational Site Number 250-020
- Investigational Site Number 250-002
- Investigational Site Number 250-016
- Investigational Site Number 300003
- Investigational Site Number 300004
- Investigational Site Number 300001
- Investigational Site Number 372001
- Investigational Site Number 376004
- Investigational Site Number 376002
- Investigational Site Number 376003
- Investigational Site Number 484004
- Investigational Site Number 484001
- Investigational Site Number 484002
- Investigational Site Number 484003
- Investigational Site Number 528001
- Investigational Site Number 528006
- Investigational Site Number 528002
- Investigational Site Number 528007
- Investigational Site Number 528003
- Investigational Site Number 528004
- Investigational Site Number 528005
- Investigational Site Number 643-009
- Investigational Site Number 643008
- Investigational Site Number 643001
- Investigational Site Number 643006
- Investigational Site Number 643007
- Investigational Site Number 643005
- Investigational Site Number 643004
- Investigational Site Number 643003
- Investigational Site Number 703002
- Investigational Site Number 703004
- Investigational Site Number 703001
- Investigational Site Number 703005
- Investigational Site Number 703003
- Investigational Site Number 724007
- Investigational Site Number 724006
- Investigational Site Number 724001
- Investigational Site Number 724005
- Investigational Site Number 724008
- Investigational Site Number 724003
- Investigational Site Number 724009
- Investigational Site Number 721002
- Investigational Site Number 724004
- Investigational Site Number 724010
- Investigational Site Number 752-002
- Investigational Site Number 752-005
- Investigational Site Number 752-006
- Investigational Site Number 752-001
- Investigational Site Number 752-03
- Investigational Site Number 752-007
- Investigational Site Number 792-001
- Investigational Site Number 792-002
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Insulin Glargine
Liraglutide
Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study. The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 < FPG ≤ 100 mg/dL (3.9 < FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation.
Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study. The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment.